Plasma

THE AUTOMOTIVE HALL OF FAME ANNOUNCES CLASS OF 2024 INDUCTEES

Retrieved on: 
Friday, February 16, 2024

DEARBORN, Mich., Feb. 16, 2024 /PRNewswire/ -- The 2024 Automotive Hall of Fame's Induction & Awards Ceremony will take place on September 19, to recognize a selection of global mobility pioneers.

Key Points: 
  • DEARBORN, Mich., Feb. 16, 2024 /PRNewswire/ -- The 2024 Automotive Hall of Fame's Induction & Awards Ceremony will take place on September 19, to recognize a selection of global mobility pioneers.
  • Widely considered the single greatest honor an individual can receive in the automotive industry, induction into the Automotive Hall of Fame is reserved for noteworthy individuals whose efforts helped shape the automotive and mobility marketplace.
  • "Once again, this year's class of inductees highlights the breadth of contributions individuals have had on this industry and all that it influences," said Sarah Cook, president of the Automotive Hall of Fame.
  • The Automotive Hall of Fame Induction & Awards Ceremony will be held on Thursday, September 19, 2024 in Detroit, Michigan.

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 15, 2024

Net product sales for the fourth quarter of 2023 were $39.9 million, compared to $25.8 million for the same period in 2022.

Key Points: 
  • Net product sales for the fourth quarter of 2023 were $39.9 million, compared to $25.8 million for the same period in 2022.
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $59.7 million, compared to $58.1 million for the same period in 2022.
  • Total other income, net, for the fourth quarter of 2023 was $5.7 million, compared to $1.1 million for the same period in 2022.
  • ET to discuss company updates as well as fourth quarter and full year 2023 financial results.

Poxel Reports Cash and Revenue for the Full Year 2023 and Provides Corporate Update

Retrieved on: 
Thursday, February 15, 2024

Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.

Key Points: 
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We remain focused and continue to concentrate all our efforts at securing financing options, prioritizing non-dilutive solution, and partnerships.
  • We’ve also progressed our advanced discussions – in some cases on an exclusive basis – with several potential partners for each of our three proprietary products.
  • Based on this conservative assumption, Poxel expects to receive 8% royalties on TWYMEEG® net sales.
  • As of December 31, 2023, total cash and cash equivalents were EUR 2.3 million (USD 2.6 million)1, as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Fernando Delgado joins Bond Vet as Chief Growth Officer

Retrieved on: 
Thursday, February 15, 2024

Bond Vet, a leading provider of veterinary primary and urgent care services in the United States, proudly announces the appointment of Fernando Delgado to the position of Chief Growth Officer (CGO).

Key Points: 
  • Bond Vet, a leading provider of veterinary primary and urgent care services in the United States, proudly announces the appointment of Fernando Delgado to the position of Chief Growth Officer (CGO).
  • Fernando joins Bond with over 20 years of marketing and business experience spanning multiple industries, including retail & hospitality, pharmaceuticals & life sciences, and consumer packaged goods.
  • “I’m thrilled to welcome Fernando to Bond Vet,” said Garrett Lewis, Chief Executive Officer.
  • In October 2023, they secured an additional $50 million from existing investors, including Warburg Pincus and Talisman Capital Partners, to continue their nationwide growth plans.

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

Retrieved on: 
Thursday, February 15, 2024

Findings also showed both doses of frexalimab provided significant reduction in new or enlarging T2 lesions, a secondary endpoint of the study.

Key Points: 
  • Findings also showed both doses of frexalimab provided significant reduction in new or enlarging T2 lesions, a secondary endpoint of the study.
  • Frexalimab is Sanofi’s novel second-generation investigational anti-CD40L antibody that has a unique method of action with the potential to address both acute and chronic neuroinflammation in MS without causing lymphocyte depletion.
  • “These published Phase 2 results for frexalimab represent important data in not only the potential treatment of MS but to the broader MS community.
  • Sanofi has initiated Phase 3 clinical trials of frexalimab in relapsing MS and non-relapsing secondary progressive MS.

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

Retrieved on: 
Thursday, February 15, 2024

Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events.

Key Points: 
  • Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events.
  • The multi-center study evaluated Afrezza in combination with basal insulin vs. multiple daily injections (MDI) of insulin in children and adolescents aged 4-17 who are living with type 1 or type 2 diabetes.
  • “We are excited to reach this milestone in exploring the potential of Afrezza for a younger generation living with diabetes,” said Dr. Kevin Kaiserman, Senior Vice President, Clinical Development and Medical Affairs for MannKind Corporation.
  • “We expect to complete a primary endpoint analysis in the fourth quarter.”
    More information on the study details is available at: https://www.clinicaltrials.gov/study/NCT04974528

Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, February 14, 2024

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments. 

Key Points: 
  • ET
    SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments.
  • "While our research and development team has started to quantify our internal data, the results, to date, are inconclusive.
  • Financial Results for the Third Quarter Ended December 31, 2023
    As of December 31, 2023, Aethlon Medical had a cash balance of approximately $8.0 million.
  • ET to review its financial results for its fiscal third quarter ended December 31, 2023 and recent corporate developments.

United Kingdom Atomic Energy Authority and Canadian Nuclear Laboratories Partner to Accelerate Fusion Energy Development

Retrieved on: 
Wednesday, February 14, 2024

OXFORD, United Kingdom and CHALK RIVER, Ontario, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The United Kingdom Atomic Energy Authority (UKAEA) and Canadian Nuclear Laboratories (CNL), have signed a collaboration framework agreement to partner on the development of technologies in relation to the management of tritium, a fusion energy fuel.

Key Points: 
  • OXFORD, United Kingdom and CHALK RIVER, Ontario, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The United Kingdom Atomic Energy Authority (UKAEA) and Canadian Nuclear Laboratories (CNL), have signed a collaboration framework agreement to partner on the development of technologies in relation to the management of tritium, a fusion energy fuel.
  • The UK-Canada Memorandum of Understanding enhances collaboration on key focus areas, including research and development, regulatory harmonisation, and skills and workforce development.
  • Stephen Wheeler, UKAEA Executive Director, said: “Fusion energy promises to be a safe, low carbon and sustainable part of the world’s future energy supply.
  • Photos from a recent visit Canadian Nuclear Laboratories visit to UK Atomic Energy Authority’s Culham Campus, in Oxfordshire, can be found here: https://ukaea.canto.global/b/JTQVC

Antibe Reports Q3 2024 Interim Financial and Operating Results

Retrieved on: 
Wednesday, February 14, 2024

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2023.

Key Points: 
  • Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2023.
  • “The results of November’s successful PK/PD study have empowered us to make considerable enhancements to the Phase II trial,” commented Dan Legault, Antibe’s CEO.
  • General and Administrative Expenses: General and administrative expenses were $2.3 million, compared to $2.2 million in fiscal Q3 2023.
  • The Company’s unaudited fiscal Q3 2024 condensed interim financial statements and MD&A are available on SEDAR.

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Wednesday, February 14, 2024

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $0.8 million in the fourth quarter of 2023, the first quarter of sales.
  • Net Loss: Net loss was $32.7 million for the fourth quarter of 2023 compared to $147.1 million for the same period in 2022.
  • ET to review its fourth quarter and full year 2023 financial results and discuss recent corporate updates.